Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clene Inc. (CLNN) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed, late clinical-stage biopharmaceutical issuer. These documents offer detailed insight into Clene’s development of CNM-Au8, its financial position, and the financing structures that support its ALS, MS, and Parkinson’s disease programs.
Investors can review current reports on Form 8-K that Clene files to describe material events. Recent 8-K filings have covered quarterly financial results and operating highlights, equity distribution agreements for at-the-market common stock offerings, prospectus supplements for additional share issuances, amendments to senior secured convertible promissory notes, and new note purchase agreements. Other 8-Ks reference press releases and scientific presentations, such as new clinical data from the REPAIR-MS and REPAIR-PD studies and regulatory updates following FDA Type C and Type B meetings.
Alongside 8-Ks, Clene’s broader SEC reporting (including Forms 10-K and 10-Q, when accessed through EDGAR) details research and development expenses, general and administrative costs, limited product and royalty revenue, and the impact of warrant and derivative liabilities. Filings also describe the terms of convertible notes, including maturity dates, interest capitalization, conversion prices into common stock, and change-of-control provisions, which are important for understanding potential dilution and capital structure.
On Stock Titan, CLNN filings are updated in near real time as they appear on EDGAR. AI-powered summaries highlight key elements of each filing, such as new financing terms, regulatory milestones, or changes in clinical development plans, helping readers quickly interpret complex legal and financial language. Users can also focus on items related to capital raises, note amendments, and other direct financial obligations that shape Clene’s runway for advancing CNM-Au8 through clinical trials and potential regulatory review.
Clene Inc. director Vallerie McLaughlin was awarded a stock option covering 3,030 shares of Common Stock. The option was granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share.
The filing shows this as a derivative acquisition with no cash paid at grant. According to the disclosure, the option vests immediately upon grant and leaves McLaughlin with 3,030 derivative shares following the transaction, reflecting a new equity-based incentive rather than an open-market share purchase.
Clene Inc. director Reed N. Wilcox reported an equity award in the form of stock options. He was granted options covering 3,306 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share.
The options vest immediately upon grant, giving him the right to purchase these shares at the stated exercise price. Following this grant, his directly held derivative securities position from this option award is reported as 3,306 options.
Clene Inc. director Alison Mosca received a grant of stock options as equity compensation. On February 19, 2026, she was awarded options for 4,201 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vested immediately upon grant, giving her the right to purchase the underlying shares at this fixed price.
Clene Inc. director David J. Matlin received a stock option grant covering 5,372 shares of Common Stock. The option was granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share and vests immediately upon grant.
Clene Inc. director Arjun JJ Desai reported an award of stock options. On February 19, 2026, he received an option grant for 3,168 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The footnote states these options vest immediately upon grant, giving him the right to purchase Clene shares at that price going forward.
Clene Inc. director Jacobovitz Shalom reported receiving a stock option grant for 4,098 shares of common stock. The option was granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share.
The option vests immediately upon grant, meaning it is fully exercisable right away. Following this award, Shalom holds stock options for 4,098 shares, all reported as directly owned. This is a compensation-related equity grant rather than an open-market share purchase.
Clene Inc. director Jonathon Gay reported receiving a grant of stock options. The award covers 3,271 shares of Common Stock, granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant, and Gay now directly holds 3,271 stock options following this acquisition.
Clene Inc. director Matthew Kiernan received a grant of stock options covering 2,755 shares of common stock. The options were granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share and vest immediately upon grant.
Clene Inc. insider activity: A Form 4 shows that on February 3, 2026, 5,559 shares of Clene Inc. common stock were sold at $4.10 per share. The shares are held indirectly through Symbiosis II, LLC, an entity associated with 10% owner Ugwumba Chidozie.
After this transaction, 550,000 Clene shares remain beneficially owned indirectly via Symbiosis II, LLC. The filing is for one reporting person and does not involve any derivative securities.
Clene Inc. insider Symbiosis II LLC has filed a notice to sell 60,842 shares of CLNN common stock. The planned sale, through Merrill Lynch on Nasdaq around 01/29/2026, has an aggregate market value of $265,731, compared with 10,333,980 shares outstanding.
The shares were acquired on 06/20/2023 via an open-market purchase for cash. The filing also lists numerous prior open-market sales by Symbiosis II LLC from December 2025 through January 29, 2026, with gross proceeds disclosed for each trade. The seller represents it is not aware of undisclosed material adverse information about Clene.